Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 12, 2026
Bank of America (BAC) Climbs +8.2% as Earnings Momentum Builds

Bank of America (BAC) Climbs +8.2% as Earnings Momentum Builds

Key Takeaways

  • BAC traded near $64.37 in mid-August 2026, roughly 8.2% above the July 13, 2026 close of $59.50, extending a steady 30-day advance.
  • Second-quarter results released July 14 beat expectations, with EPS of $1.21, revenue of $31.6 billion, and net income up 27% year over year.
  • Momentum was broad-based, supported by net interest income, record equities trading, and a 50% increase in investment banking fees.
  • Management raised full-year operating-leverage guidance to 300–400 basis points and expects NII growth at the upper end of its 6%–8% range.
  • Analysts remain largely constructive, with several firms lifting price targets after earnings; key watch items include the rate path, credit quality, and regulatory developments.

Where BAC Stands in the Market Right Now

Bank of America shares have maintained an orderly upward grind through July and early August. The stock was changing hands near $64.37 in midday trading on August 12, 2026, compared with $59.50 at the July 13 close, a gain of approximately 8.2% over roughly 30 days. The advance has been supported by a strong second-quarter earnings season for large U.S. banks, resilient consumer spending, and an improving investment-banking and trading backdrop. Financial-sector sentiment has also benefited from rebounding capital-markets activity and broadly stable credit trends. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Bank of America’s Business and Competitive Landscape

Bank of America Corporation is a diversified financial services company headquartered in Charlotte, North Carolina. The bank operates through Consumer Banking, Global Wealth and Investment Management, Global Banking, and Global Markets, serving consumers, small and middle-market businesses, large corporations, governments, and institutional investors. Its offerings span deposits, lending, credit cards, mortgages, wealth management, investment banking, sales and trading, and treasury services.

The company competes with peers such as JPMorgan Chase (JPM), Wells Fargo (WFC), Citigroup (C), and Morgan Stanley (MS). BAC's competitive strengths include a leading deposit franchise, scale across lending and capital markets, strong digital adoption, and a diversified revenue base. The bank has reported 12 consecutive quarters of average deposit growth and maintains relationships with 78% of the Global Fortune 500 and 96% of the U.S. Fortune 1,000. Investors follow the stock for its sensitivity to interest rates, consumer credit trends, capital-markets activity, and shareholder returns.

Key Drivers Behind the Recent Advance

The central catalyst in the past 30 days was the July 14 second-quarter earnings report. BAC reported EPS of $1.21, above consensus estimates, on revenue of $31.6 billion, up 15% year over year. Net income rose 27% to $9.1 billion. Net interest income increased 9% to about $16.0 billion, while noninterest income climbed 22%. Sales and trading revenue reached $7.2 billion, up 33%, with equities trading rising roughly 70% to a record $3.6 billion. Investment banking fees increased 50% to more than $2.1 billion, and the efficiency ratio improved to 59% with operating leverage of 6.6%.

Credit quality remained stable. The provision for credit losses was approximately $1.4 billion, and the net charge-off ratio improved to 0.47%. The company returned $8.0 billion to shareholders through $6.0 billion in buybacks and $2.0 billion in dividends. Management now expects full-year operating leverage of 300–400 basis points and net interest income growth at the upper end of the 6%–8% range, with guidance assuming a 25-basis-point rate increase in September.

After the report, several analysts lifted targets. UBS reiterated a Buy rating with a $70 price target, Barclays maintained a Buy rating with a $72 target, and JPMorgan raised its target to $68. The consensus rating remains Buy, with average 12-month targets clustering in the high-$60s. Separately, BAC disclosed it may face monetary penalties tied to deficiencies in its anti-money-laundering program, with a potential resolution with the OCC approaching. The bank also continued to highlight AI adoption, citing more than 300 approved AI use cases, 114 live generative AI use cases, and over 200,000 employees using AI-enabled capabilities. From what I see, the breadth of the earnings beat and the raised guidance stand out as particularly supportive.

What to Watch Going Forward

Looking ahead, investors are likely to monitor third-quarter earnings, net interest income, and the net interest yield as the interest-rate outlook evolves. Management's guidance assumes a September rate increase, and the bank's disclosed sensitivity indicates that a 100-basis-point shift above the forward curve could add about $1.0 billion to net interest income over 12 months, while a 100-basis-point decline could reduce it by about $2.2 billion. Capital-markets pipelines, trading volumes, wealth-management flows, and loan growth will also shape revenue momentum.

Other factors include consumer and commercial credit trends, expense discipline and operating leverage, the resolution of the AML-related regulatory matter with the OCC, and the pace of capital return through buybacks and dividends. AI-driven productivity initiatives remain a strategic theme, while deposit pricing competition and the broader economic backdrop will influence sentiment. These considerations are informational and do not constitute financial advice. I’m watching this closely as the rate path and credit metrics develop.

Using Tickeron’s AI Trading Bots for Research

In my own analysis, I often turn to Tickeron’s AI Trading Bots to explore systematic strategies across different timeframes and performance metrics. The platform helps filter ideas by strategy and consistency, which can provide useful context when evaluating names like BAC alongside broader market signals. It has become a regular part of how I cross-check momentum and pattern ideas without replacing traditional fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: BAC

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


Momentum Indicator for BAC turns positive, indicating new upward trend

BAC saw its Momentum Indicator move above the 0 level on July 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BAC advanced for three days, in of 342 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 278 cases where BAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for BAC turned negative on July 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BAC broke above its upper Bollinger Band on July 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. BAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 19, placing this stock slightly worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (1.953). P/E Ratio (14.781) is within average values for comparable stocks, (16.333). Projected Growth (PEG Ratio) (1.090) is also within normal values, averaging (1.625). BAC has a moderately low Dividend Yield (0.018) as compared to the industry average of (0.025). P/S Ratio (4.027) is also within normal values, averaging (4.356).

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 217.83B. The market cap for tickers in the group ranges from 1.04M to 962.37B. JPM holds the highest valuation in this group at 962.37B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was 1%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 24%. BNY experienced the highest price growth at 2%, while HSBC experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was -39%. For the same stocks of the Industry, the average monthly volume growth was -13% and the average quarterly volume growth was -63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 68
P/E Growth Rating: 30
Price Growth Rating: 41
SMR Rating: 8
Profit Risk Rating: 19
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
BAC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Profile
Details
Industry
Major Banks
Address
100 North Tryon Street
Phone
+1 704 386-5681
Employees
213000
Web
https://www.bankofamerica.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.